David T. Yeung,for the Australasian Leukaemia and Lymphoma Group,Michael P. Osborn,for the Australasian Leukaemia and Lymphoma Group,Deborah L. White,for the Australasian Leukaemia and Lymphoma Group,Susan Branford,for the Australasian Leukaemia and Lymphoma Group,Jodi Braley,for the Australasian Leukaemia and Lymphoma Group,Alan Herschtal,for the Australasian Leukaemia and Lymphoma Group,Michael Kornhauser,for the Australasian Leukaemia and Lymphoma Group,Samar Issa,for the Australasian Leukaemia and Lymphoma Group,Devendra K. Hiwase,for the Australasian Leukaemia and Lymphoma Group,Mark Hertzberg,for the Australasian Leukaemia and Lymphoma Group,Anthony P. Schwarer,for the Australasian Leukaemia and Lymphoma Group,Robin Filshie,for the Australasian Leukaemia and Lymphoma Group,Christopher K. Arthur,for the Australasian Leukaemia and Lymphoma Group,Yiu Lam Kwan,for the Australasian Leukaemia and Lymphoma Group,Judith Trotman,for the Australasian Leukaemia and Lymphoma Group,Cecily J. Forsyth,for the Australasian Leukaemia and Lymphoma Group,John Taper,for the Australasian Leukaemia and Lymphoma Group,David M. Ross,for the Australasian Leukaemia and Lymphoma Group,Jennifer Beresford,for the Australasian Leukaemia and Lymphoma Group,Constantine Tam,for the Australasian Leukaemia and Lymphoma Group,Anthony K. Mills,for the Australasian Leukaemia and Lymphoma Group,Andrew P. Grigg,for the Australasian Leukaemia and Lymphoma Group,Timothy P. Hughes,for the Australasian Leukaemia and Lymphoma Group

View Articletitled, TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Supplemental data

Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score–matched study
Clinical Trials & Observations

Matthew Kang,Majed Alahmadi,Sonja Sawh,Michael J. Kovacs,Alejandro Lazo-Langner

View Articletitled, Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score–matched study

Supplemental data

HEMATOPOIESIS AND STEM CELLS

Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia

Iléana Antony-Debré,Vladimir T. Manchev,Nathalie Balayn,Dominique Bluteau,Cécile Tomowiak,Céline Legrand,Thierry Langlois,Olivia Bawa,Lucie Tosca,Gérard Tachdjian,Bruno Leheup,Najet Debili,Isabelle Plo,Jason A. Mills,Deborah L. French,Mitchell J. Weiss,Eric Solary,Remi Favier,William Vainchenker,Hana Raslova

View Articletitled, Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia

Supplemental data

Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl

Nan Xiao,Suparna Laha,Shankar P. Das,Kayla Morlock,Jonathan L. Jesneck,Glen D. Raffel

View Articletitled, Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl

IMMUNOBIOLOGY

Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b

Lorenz Jahn,Pleun Hombrink,Chopie Hassan,Michel G. D. Kester,Dirk M. van der Steen,Renate S. Hagedoorn,J. H. Frederik Falkenburg,Peter A. van Veelen,Mirjam H. M. Heemskerk

View Articletitled, Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b

Supplemental data

LYMPHOID NEOPLASIA

An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup
Clinical Trials & Observations

Fong Chun Chan,Adele Telenius,Shannon Healy,Susana Ben-Neriah,Anja Mottok,Raymond Lim,Marie Drake,Sandy Hu,Jiarui Ding,Gavin Ha,David W. Scott,Robert Kridel,Ali Bashashati,Sanja Rogic,Nathalie Johnson,Ryan D. Morin,Lisa M. Rimsza,Laurie Sehn,Joseph M. Connors,Marco A. Marra,Randy D. Gascoyne,Sohrab P. Shah,Christian Steidl

View Articletitled, An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup

Supplemental data

Identification of CD34⁺ and CD34⁻ leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia

Yuki Aoki,Takashi Watanabe,Yoriko Saito,Yoko Kuroki,Atsushi Hijikata,Masatoshi Takagi,Daisuke Tomizawa,Mariko Eguchi,Minenori Eguchi-Ishimae,Akiko Kaneko,Rintaro Ono,Kaori Sato,Nahoko Suzuki,Saera Fujiki,Katsuyoshi Koh,Eiichi Ishii,Leonard D. Shultz,Osamu Ohara,Shuki Mizutani,Fumihiko Ishikawa

View Articletitled, Identification of CD34+ and CD34− leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia

Supplemental data

Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment

Marzenna Blonska,Yifan Zhu,Hubert H. Chuang,M. James You,Kranthi Kunkalla,Francisco Vega,Xin Lin

View Articletitled, Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment

Supplemental data

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Muhammad A. Mir,Matthew J. Maurer,Steven C. Ziesmer,Susan L. Slager,Thomas Habermann,William R. Macon,Brian K. Link,Sergei Syrbu,Thomas Witzig,Jonathan W. Friedberg,Oliver Press,Michael LeBlanc,James R. Cerhan,Anne Novak,Stephen M. Ansell

View Articletitled, Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Supplemental data

Genetic inactivation of TRAF3 in canine and human B-cell lymphoma

Kevin R. Bushell,Yukyoung Kim,Fong Chun Chan,Susana Ben-Neriah,Andrew Jenks,Miguel Alcaide,Daniel Fornika,Bruno M. Grande,Sarah Arthur,Randy D. Gascoyne,Christian Steidl,Ryan D. Morin

View Articletitled, Genetic inactivation of TRAF3 in canine and human B-cell lymphoma

Supplemental data

PLATELETS AND THROMBOPOIESIS

Identification of a new dysfunctional platelet P2Y₁₂ receptor variant associated with bleeding diathesis

Anna Lecchi,Cristina Razzari,Silvia Paoletta,Arnaud Dupuis,Lea Nakamura,Philippe Ohlmann,Christian Gachet,Kenneth A. Jacobson,Barbara Zieger,Marco Cattaneo

View Articletitled, Identification of a new dysfunctional platelet P2Y12 receptor variant associated with bleeding diathesis

Dynamin 2–dependent endocytosis is required for normal megakaryocyte development in mice

Markus Bender,Silvia Giannini,Renata Grozovsky,Terese Jönsson,Hilary Christensen,Fred G. Pluthero,Amy Ko,Ann Mullally,Walter H. A. Kahr,Karin M. Hoffmeister,Hervé Falet

View Articletitled, Dynamin 2–dependent endocytosis is required for normal megakaryocyte development in mice

RED CELLS, IRON, AND ERYTHROPOIESIS

A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor

Eyayu Belay,Chris P. Miller,Amanda N. Kortum,Beverly Torok-Storb,C. Anthony Blau,David W. Emery

View Articletitled, A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor

Supplemental data

THROMBOSIS AND HEMOSTASIS

von Willebrand factor is a cofactor in complement regulation
Brief Report

Shuju Feng,Xiaowen Liang,Michael H. Kroll,Dominic W. Chung,Vahid Afshar-Kharghan

View Articletitled, von Willebrand factor is a cofactor in complement regulation

Supplemental data

VASCULAR BIOLOGY

Loss of DGKε induces endothelial cell activation and death independently of complement activation

Sarah Bruneau,Mélanie Néel,Lubka T. Roumenina,Marie Frimat,Lætitia Laurent,Véronique Frémeaux-Bacchi,Fadi Fakhouri

View Articletitled, Loss of DGKε induces endothelial cell activation and death independently of complement activation

Supplemental data

BLOOD WORK

Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy

Yair Herishanu,Ben-Zion Katz

View Articletitled, Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy

ERRATA

Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014;124(3):334-343.

View Articletitled, Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014;124(3):334-343.

Köffel R, Meshcheryakova A, Warszawska J, et al. Monocytic cell differentiation from band-stage neutrophils under inflammatory conditions via MKK6 activation. Blood. 2014;124(17):2713-2724.

View Articletitled, Köffel R, Meshcheryakova A, Warszawska J, et al. Monocytic cell differentiation from band-stage neutrophils under inflammatory conditions via MKK6 activation. Blood. 2014;124(17):2713-2724.

Cover Image

Cover Image

Wright-Giemsa–stained cytospin of primitive megakaryocytes differentiated from a novel bipotential erythrocyte-megakaryocyte precursor population expanded from human cord blood CD34⁺ cells with a hyperactive Mpl-based cell growth switch. See the article by Belay et al on page 1025.
Front Matter
Table of Contents
Back Matter
Advertising
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Licking the wound with procoagulant vesicles

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

CAR T-cells in autoimmunity: game changer or stepping stone?

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Issue Archive

Table of Contents

INSIDE BLOOD COMMENTARIES

BLOOD SPOTLIGHT

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors Clinical Trials & Observations

HOW I TREAT

How I treat type 2 variant forms of von Willebrand disease Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets Clinical Trials & Observations

Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score–matched study Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY

LYMPHOID NEOPLASIA

An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup Clinical Trials & Observations

PLATELETS AND THROMBOPOIESIS

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

von Willebrand factor is a cofactor in complement regulation Brief Report

VASCULAR BIOLOGY

BLOOD WORK

ERRATA

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Clinical Trials & Observations

How I treat type 2 variant forms of von Willebrand disease
Clinical Trials & Observations

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
Clinical Trials & Observations

Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score–matched study
Clinical Trials & Observations

An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup
Clinical Trials & Observations

von Willebrand factor is a cofactor in complement regulation
Brief Report